Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700666 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ALMNACYP2D6 | |
| SCHEMBL23700664 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ALMNACYP2D6 | |
| SCHEMBL29869134 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ALMNACYP2D6 | |
| SCHEMBL23674635 | 0.90 | CFTR (0.32) | CYP2C19 | |
| SCHEMBL23674633 | 0.90 | CFTR (0.32) | CYP2C19 | |
| SCHEMBL23674634 | 0.90 | CFTR (0.32) | CYP2C19 | |
| SCHEMBL24985924 | 0.89 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ALMNACYP2D6 | |
| SCHEMBL26526718 | 0.89 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ALMNACYP2D6 | |
| SCHEMBL23674676 | 0.87 | CFTR (0.33) | ROCK2ROCK1 | |
| SCHEMBL23700560 | 0.87 | CFTR (0.33) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | ALDH1A1 1686/4885MEN1 1492/4885KMT2A 2438/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | ALDH1A1 1686/4885MEN1 1492/4885KMT2A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.